MD20150054A2 - Produs de comicronizare cu conţinut de un modulator selectiv al receptorului de progesteron - Google Patents

Produs de comicronizare cu conţinut de un modulator selectiv al receptorului de progesteron

Info

Publication number
MD20150054A2
MD20150054A2 MDA20150054A MD20150054A MD20150054A2 MD 20150054 A2 MD20150054 A2 MD 20150054A2 MD A20150054 A MDA20150054 A MD A20150054A MD 20150054 A MD20150054 A MD 20150054A MD 20150054 A2 MD20150054 A2 MD 20150054A2
Authority
MD
Moldova
Prior art keywords
receptor modulator
selective progesterone
micronisation
product
micronisation product
Prior art date
Application number
MDA20150054A
Other languages
English (en)
Russian (ru)
Other versions
MD4546C1 (ro
MD4546B9 (ro
MD4546B1 (ro
Inventor
Florian Battung
Pierre-Yves Juvin
Jérôme Hecq
Aude Colin
Original Assignee
Laboratoire Hra-Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Laboratoire Hra-Pharma filed Critical Laboratoire Hra-Pharma
Publication of MD20150054A2 publication Critical patent/MD20150054A2/ro
Publication of MD4546B1 publication Critical patent/MD4546B1/ro
Publication of MD4546B9 publication Critical patent/MD4546B9/ro
Publication of MD4546C1 publication Critical patent/MD4546C1/ro

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A61K9/4825—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Bidet-Like Cleaning Device And Other Flush Toilet Accessories (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Obiectul prezentei invenţii este un produs de comicronizare ce cuprinde: un ingredient activ selectat din grupul format din modulatori selectivi ai receptorului de progesteron, metaboliţi ai acestora şi amestecuri de metaboliţi, şi un excipient polimeric în bază de N-vinil-2-pirolidonă.Invenţia se referă, de asemenea, la o compoziţie farmaceutică care cuprinde produsul de comicronizare menţionat şi la utilizările terapeutice ale acesteia.
MDA20150054A 2012-11-08 2013-11-07 Produs de comicronizare cu conţinut de un modulator selectiv al receptorului de progesteron MD4546C1 (ro)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR1260605A FR2997628B1 (fr) 2012-11-08 2012-11-08 Produit de co-micronisation comprenant un modulateur selectif des recepteurs a la progesterone
PCT/FR2013/052671 WO2014072647A1 (fr) 2012-11-08 2013-11-07 Produit de co-micronisation comprenant un modulateur selectif du recepteur a la progesterone

Publications (4)

Publication Number Publication Date
MD20150054A2 true MD20150054A2 (ro) 2015-10-31
MD4546B1 MD4546B1 (ro) 2018-01-31
MD4546B9 MD4546B9 (ro) 2018-08-31
MD4546C1 MD4546C1 (ro) 2019-03-31

Family

ID=47714259

Family Applications (1)

Application Number Title Priority Date Filing Date
MDA20150054A MD4546C1 (ro) 2012-11-08 2013-11-07 Produs de comicronizare cu conţinut de un modulator selectiv al receptorului de progesteron

Country Status (21)

Country Link
US (1) US20150258118A1 (ro)
EP (1) EP2916823B1 (ro)
JP (1) JP2015536969A (ro)
CN (1) CN105073098B (ro)
CR (1) CR20150298A (ro)
CY (1) CY1118884T1 (ro)
DK (1) DK2916823T3 (ro)
EA (1) EA029643B1 (ro)
EC (1) ECSP15022505A (ro)
ES (1) ES2625012T3 (ro)
FR (1) FR2997628B1 (ro)
GE (1) GEP201706648B (ro)
HR (1) HRP20170686T1 (ro)
LT (1) LT2916823T (ro)
MD (1) MD4546C1 (ro)
PL (1) PL2916823T3 (ro)
PT (1) PT2916823T (ro)
RS (1) RS55956B1 (ro)
SI (1) SI2916823T1 (ro)
UA (1) UA115573C2 (ro)
WO (1) WO2014072647A1 (ro)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106265533A (zh) * 2016-10-10 2017-01-04 朱隆娅 一种阿德呋啉颗粒剂及其制备方法
FR3060389B1 (fr) * 2016-12-20 2019-05-31 Laboratoire Hra-Pharma Comprime enrobe comprenant de l'ulipristal acetate ou un de ses metabolites
EP3895691A1 (en) 2020-04-15 2021-10-20 LTS Lohmann Therapie-Systeme AG Ulipristal acetate otf
US11878025B2 (en) 2021-09-06 2024-01-23 Slayback Pharma Llc Pharmaceutical compositions of mifepristone

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4954490A (en) * 1988-06-23 1990-09-04 Research Triangle Institute 11 β-substituted progesterone analogs
US5759577A (en) * 1995-01-17 1998-06-02 American Home Products Corporation Controlled release of steroids from sugar coatings
JP2004099442A (ja) * 2002-09-04 2004-04-02 Nisshin Pharma Inc 難溶性薬物含有製剤およびその製造方法
ES2212912B1 (es) * 2003-01-22 2005-10-01 Crystal Pharma, S.A. Procedimiento para la obtencion de 17alfa-acetoxi-11beta-(4-n,n-dimetilaminofenil)-19-norpregna-4,9-dien-3,20-diona.
EP1768625B1 (en) 2004-07-09 2011-02-09 The Population Council, Inc. Sustained release compositions containing progesterone receptor modulators
SI3263112T1 (sl) * 2006-10-24 2020-10-30 Allergan Pharmaceuticals International Limited Sestavki in metode za zaviranje endometrijskih proliferacij
MX2009006912A (es) * 2006-12-28 2009-08-12 Repros Therapeutics Inc Metodos y formulaciones para biodisponibilidad mejorada de antiprogestinas.
JP2008169135A (ja) * 2007-01-11 2008-07-24 Takada Seiyaku Kk グリメピリド組成物の製造方法
US8299050B2 (en) * 2008-01-29 2012-10-30 Laboratoire Hra-Pharma Method for treating uterine fibroids
TWI539953B (zh) * 2008-04-28 2016-07-01 瑞波若斯治療學公司 用於治療乳癌之組成物和方法
US8512745B2 (en) * 2008-12-08 2013-08-20 Laboratoire Hra Pharma Ulipristal acetate tablets
SI2419108T1 (sl) 2009-04-14 2017-02-28 Laboratorie Hra Pharma Metoda za kontracepcijo na zahtevo
EP2535114A4 (en) * 2009-11-13 2015-11-18 Moriroku Chemicals Company Ltd PROCESS FOR PRODUCING FINE POWDER AND FINE POWDER PRODUCED ACCORDING TO THIS METHOD
FR2988610B1 (fr) * 2012-03-30 2014-10-31 Effik Progestatif co-micronise avec un polymere portant le groupe pyrrolidone, composition et utilisations
CN102871977A (zh) * 2012-10-19 2013-01-16 北京紫竹药业有限公司 醋酸优力司特分散片及其制备方法

Also Published As

Publication number Publication date
UA115573C2 (uk) 2017-11-27
FR2997628A1 (fr) 2014-05-09
FR2997628B1 (fr) 2015-01-16
JP2015536969A (ja) 2015-12-24
CY1118884T1 (el) 2018-01-10
ECSP15022505A (es) 2016-01-29
MD4546C1 (ro) 2019-03-31
EP2916823A1 (fr) 2015-09-16
HRP20170686T1 (hr) 2017-09-08
CN105073098A (zh) 2015-11-18
DK2916823T3 (en) 2017-05-15
PT2916823T (pt) 2017-05-22
US20150258118A1 (en) 2015-09-17
LT2916823T (lt) 2017-07-25
EA201500514A1 (ru) 2015-09-30
CN105073098B (zh) 2019-02-19
CR20150298A (es) 2015-08-14
SI2916823T1 (sl) 2017-08-31
WO2014072647A1 (fr) 2014-05-15
PL2916823T3 (pl) 2017-08-31
MD4546B9 (ro) 2018-08-31
EA029643B1 (ru) 2018-04-30
ES2625012T3 (es) 2017-07-18
RS55956B1 (sr) 2017-09-29
MD4546B1 (ro) 2018-01-31
EP2916823B1 (fr) 2017-02-15
GEP201706648B (en) 2017-03-27

Similar Documents

Publication Publication Date Title
MX2022010168A (es) Moduladores de calpainas y usos terapeuticos de los mismos.
PH12015502621A1 (en) Estrogen receptor modulator and uses thereof
PH12014502095A1 (en) Estrogen receptor modulators and uses thereof
WO2013120104A3 (en) Modulators of methyl modifying enzymes, compositions and uses thereof
AU2013225533A8 (en) Amido spirocyclic amide and sulfonamide derivatives
IN2012DN02984A (ro)
AU2013317899A8 (en) Biodegradable microcapsules containing filling material
MX2015009773A (es) Moduladores de receptores nmda de espiro-lactama y sus usos.
SG10201907588XA (en) Androgen Receptor Modulators And Uses Thereof
WO2011138678A3 (en) Compositions, gels and foams with rheology modulators and uses thereof
EP3072506A4 (en) Carrier for drug delivery and conjugate, composition containing same, and method for administering same
WO2012170931A3 (en) Compounds that modulate intracellular calcium
MX2014014590A (es) Microcapsulas que contienen retinoides, su procedimiento de preparacion y composiciones farmaceuticas que los contienen.
MX2015008021A (es) Composiciones y metodos para administracion transdermica de hormonas y otros agentes medicos.
MD4591C1 (ro) Dispersie solidă a unui modulator selectiv al receptorului de progesteron
WO2012170951A3 (en) Compounds that modulate intracellular calcium
MD20150053A2 (ro) Produs de comicronizare cu conţinut de acetat de ulipristal
MD20150054A2 (ro) Produs de comicronizare cu conţinut de un modulator selectiv al receptorului de progesteron
MX364934B (es) Agente para prevenir y/o tratar dolor neuropático periférico causado por fármaco contra el cáncer.
EP2875814A4 (en) LIQUID COMPOSITION CONTAINING TAXANE ACTIVE INGREDIENT, MANUFACTURING METHOD THEREOF, AND LIQUID MEDICINAL PREPARATION
PH12014501573A1 (en) Topical pharmaceutical compositions comprising bexarotene and a corticosteroids
MX2015003034A (es) Jeringa que contiene una composicion, en particular farmaceutica, que comprende inmunoglobulinas, su metodo de fabricacion y uso.
EP2547203A4 (en) CCR5 MODULATORS FOR HIV TREATMENT
WO2014044869A3 (de) Medizinisches präparat umfassend einen träger mit polyhexanid oder octenidin

Legal Events

Date Code Title Description
FG4A Patent for invention issued
KA4A Patent for invention lapsed due to non-payment of fees (with right of restoration)
MM4A Patent for invention definitely lapsed due to non-payment of fees